Evaluating Efficacy and Safety Data from the EMERALD Trial

Efficacy analyses from the EMERALD trial demonstrated that the oral SERD elacestrant improved progression-free survival, particularly in patients harboring ESR1 mutations, highlighting its potential to overcome endocrine resistance. Safety data indicated a generally manageable profile, with adverse events consistent with known class effects and few treatment discontinuations due to toxicity. The trial’s findings underscore the balance between clinical benefit and tolerability, supporting the role of the oral SERD in later-line therapy. Overall, EMERALD provides clinically meaningful evidence that informs personalized treatment decisions for patients with advanced ER+/HER2- disease.